Neuro-Oncology Reviews

Volume 26 Number 1
15 January 2024

Home > Publications > Neuro-Oncology Reviews > Volume 26, Year 2024 > Number 1, 15 January

Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M.
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Lancet Oncol. 2024 Jan 2;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. PMID: 38181810. Review, Guidelines˰ ˍ

Tosi U, Souweidane M.
Diffuse Midline Gliomas: Challenges and New Strategies in a Changing Clinical Landscape.
Cancers (Basel). 2024 Jan 2;16(1):219. doi: 10.3390/cancers16010219. PMID: 38201646. Review. ˍ

Vermeulen E, Vander Mijnsbrugge AS, Brock S, Vaeyens F, Dirven I, Ciçek A, Marcelis W, Klein S, Bruneau M, Neyns B, Duerinck J.
Successful Treatment with Dabrafenib/Trametinib of a Malignantly Transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: A Case Report and Review of the Literature.
Case Rep Oncol. 2024 Jan 3;17(1):10-16. doi: 10.1159/000534731. PMID: 38179547. Case report, Review. ˍ

Youssef G, Wen PY.
Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Curr Neurol Neurosci Rep. 2024 Jan 3. doi: 10.1007/s11910-023-01329-4. PMID: 38170429. Review˰ ˍ

Besbris JM, Taylor LP.
Palliative Care in Neuro-Oncology.
Semin Neurol. 2024 Jan 4. doi: 10.1055/s-0043-1777703. PMID: 38176423. Review˰ ˍ

Bonm AV, Taylor LP.
Management of Neurologic Complications in Patients with Brain and Spine Tumors.
Semin Neurol. 2024 Jan 4. doi: 10.1055/s-0043-1777422. PMID: 38176424. Review˰ ˍ

Pinkiewicz M, Pinkiewicz M, Walecki J, Zaczyński A, Zawadzki M.
Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood-Brain Barrier Disruption.
Cancers (Basel). 2024 Jan 4;16(1):236. doi: 10.3390/cancers16010236. PMID: 38201663. Review. ˍ

Buccilli B, Rodriguez Molina MA, Redrovan Palomeque DP, Herrera Sabán CA, Caliwag FMC, Contreras Flores CJS, Abeysiriwardana CWJ, Diarte E, Arruarana VS, Calderon Martinez E.
Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment Response.
Cureus. 2024 Jan 5;16(1):e51712. doi: 10.7759/cureus.51712. PMID: 38313884. Review. ˍ

Dong C, Yu X, Jin K, Qian J.
Overcoming brain barriers through surface-functionalized liposomes for glioblastoma therapy; current status, challenges and future perspective.
Nanomedicine (Lond). 2024 Jan 5. doi: 10.2217/nnm-2023-0172. PMID: 38180008. Review˰ ˍ

Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, Chandra J.
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
J Exp Clin Cancer Res. 2024 Jan 5;43(1):12. doi: 10.1186/s13046-023-02923-7. PMID: 38183103. Review. ˍ


Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G.
Glioblastoma vaccines: past, present, and opportunities.
EBioMedicine. 2024 Jan 5;100:104963. doi: 10.1016/j.ebiom.2023.104963. PMID: 38183840. Review. ˍ

Cuneo A, Murinova N.
Headache Management in Individuals with Brain Tumor.
Semin Neurol. 2024 Jan 6. doi: 10.1055/s-0043-1777423. PMID: 38183973. Review. ˍ

McGranahan TM, Figuracion KC, Goldberg M, Sheppard DP.
Neurologic Complications in Adult Cancer Survivorship.
Semin Neurol. 2024 Jan 6. doi: 10.1055/s-0043-1777424. PMID: 38183974. Review˰ ˍ

Ding X, Liang T, Liang B, Zhou X, Chen J, Gao H, Wang F, Zheng X, Feng E.
Clinical characteristics and prognostic analysis of patients with HIV and glioma: A case series and literature review.
Exp Ther Med. 2024 Jan 8;27(2):90. doi: 10.3892/etm.2024.12380. PMID: 38274346. Case report, Review. ˍ

Guterres A, Filho PNS, Moura-Neto V.
Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses.
Vaccines (Basel). 2024 Jan 8;12(1):61. doi: 10.3390/vaccines12010061. PMID: 38250874. Perspective. ˍ

Santorsola M, Caraglia M, Ottaiano A.
Editorial: Type 2 diabetes and cancer: clinical and molecular interactions.
Front Med (Lausanne). 2024 Jan 8;10:1345732. doi: 10.3389/fmed.2023.1345732. PMID: 38259859. Editorial. ˍ

Zhang H, Chen Y, Jiang X, Gu Q, Yao J, Wang X, Wu J.
Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis.
Front Pharmacol. 2024 Jan 8;14:1333124. doi: 10.3389/fphar.2023.1333124. PMID: 38259287. Bibliometric analysis. ˍ

Kinslow CJ, Garton ALA, Rae AI, Kocakavuk E, McKhann GM, Cheng SK, Sisti MB, Bruce JN, Wang TJC.
Extent of resection for low-grade gliomas - Prognostic or therapeutic?
Clin Neurol Neurosurg. 2024 Jan 9;236:108117. doi: 10.1016/j.clineuro.2024.108117. PMID: 38219356. Editorial˰ ˍ

Yu P, Wang Y, Su F, Chen Y.
Comparing [18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a systematic review and meta-analysis.
Front Oncol. 2024 Jan 10;13:1346951. doi: 10.3389/fonc.2023.1346951. PMID: 38269019. Review, Meta-analysis. ˍ

Dagher R, Gad M, da Silva de Santana P, Sadeghi MA, Yewedalsew SF, Gujar SK, Yedavalli V, Köhler CA, Khan M, Tavora DGF, Kamson DO, Sair HI, Luna LP.
Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-023-04528-8. PMID: 38212574. Review, Meta-analysis˰ ˍ

Shikalov A, Koman I, Kogan NM.
Targeted Glioma Therapy-Clinical Trials and Future Directions.
Pharmaceutics. 2024 Jan 11;16(1):100. doi: 10.3390/pharmaceutics16010100. PMID: 38258110. Review. ˍ

Cho S, Chu MK.
Headache in Brain Tumors.
Neurol Clin. 2024 Jan 12;42(2):487-496. doi: 10.1016/j.ncl.2023.12.004. PMID: 38575261. Review˰ ˍ

Zheng X, Yang J, Hou Y, Shi X, Liu K.
Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP).
Eur J Med Res. 2024 Jan 12;29(1):51. doi: 10.1186/s40001-023-01631-4. PMID: 38216970. Review. ˍ

*Zhou Y, Liu M, Huang X, Liu Z, Sun Y, Wang M, Huang T, Wang X, Chen L, Jiang X.
Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles.
Front Oncol. 2024 Jan 12;13:1307924. doi: 10.3389/fonc.2023.1307924. PMID: 38293697. Bibliometric analysis. ˍ

Wang H, Yang J, Li X, Zhao H.
Current state of immune checkpoints therapy for glioblastoma.
Heliyon. 2024 Jan 13;10(2):e24729. doi: 10.1016/j.heliyon.2024.e24729. PMID: 38298707. Review. ˍ

Palavani LB, de Barros Oliveira L, Reis PA, Batista S, Santana LS, de Freitas Martins LP, Rabelo NN, Bertani R, Welling LC, Figueiredo EG, Paiva WS, Neville IS.
Efficacy and Safety of Intraoperative Radiotherapy for High-Grade Gliomas: A Systematic Review and Meta-Analysis.
Neurosurg Rev. 2024 Jan 15;47(1):47. doi: 10.1007/s10143-024-02279-2. PMID: 38221545. Review, Meta-analysis˰ ˍ